Evidence map›Paper›PMID 38031732›Full record

ArticleAmerican journal of physiology. Renal physiology2024

Role of protease-activated receptor 4 in mouse models of acute and chronic kidney injury.

Kevin Erreger, Shirong Cao, Yu Pan, Mengdi Jiang, Ming-Zhi Zhang, Raymond C Harris, Heidi E Hamm

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Renal physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Serine proteases and protease-activated receptors signaling in the kidney.American journal of physiology. Cell physiology · 2025
    Review
  4. Guidelines on antibody use in physiology research.American journal of physiology. Renal physiology · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kevin ErregerDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States.ORCID 0000-0001-5801-2344
Shirong CaoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Yu PanDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Mengdi JiangDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States.ORCID 0000-0002-4805-0504
Ming-Zhi ZhangDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Raymond C HarrisDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
Heidi E HammDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States.ORCID 0000-0001-5437-5287
Vanderbilt University Medical Center · USVanderbilt University · US

Funding

The Role of the EGF Receptor in Acute and Chronic Renal InjuryR01DK051265 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RAYMOND C. HARRIS, Mingzhi Zhang · 1997 to 2026
$10.1M
The role of the innate immune cell cyclooxygenase/prostaglandin system in blood pressureregulationR01DK062794 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RAYMOND C. HARRIS, Mingzhi Zhang · 2003 to 2026
$9.4M
The Role of renal macrophages in recovery from renal injuryR01DK095785 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RAYMOND C. HARRIS, Mingzhi Zhang · 2013 to 2026
$6.7M
Vanderbilt O'Brien Kidney Center - Core D - Clinical and Translational CoreP30DK114809 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILSON, MATTHEW H · 2017 to 2021
$5.9M
Targeting PAR4 in Thrombotic Disorders:Pharmacogenomic ApproachR01HL133923 · NHLBI · VANDERBILT UNIVERSITY · PI HAMM, HEIDI E · 2017 to 2020
$2.3M
Cerebrovascular involvement in Alzheimer's Disease: PAR4 AntagonismRF1AG068623 · NIA · VANDERBILT UNIVERSITY · PI HAMM, HEIDI E, MEILER, JENS · 2021 to 2021
$2.2M
Cerebrovascular involvement in Alzheimer's Disease: PAR4 AntagonismR01AG068623 · NIA · VANDERBILT UNIVERSITY · PI HAMM, HEIDI E, MEILER, JENS · 2024 to 2025
$1.4M
Role of Protease Activated Receptor 4 in cerebrovascular dysfunction and dementiaR21AG073891 · NIA · VANDERBILT UNIVERSITY · PI HAMM, HEIDI E · 2021 to 2022
$462k
NHLBI NIH HHS R01 HL133923NIA NIH HHS R01 AG068623NIA NIH HHS R21 AG073891NIA NIH HHS RF1 AG068623NIDDK NIH HHS P30 DK114809NIDDK NIH HHS R01 DK051265NIDDK NIH HHS R01 DK062794NIDDK NIH HHS R01 DK095785
6 · The paper itself

Abstract

Protease-activated receptor 4 (PAR4) is a G protein-coupled receptor activated by thrombin. In the platelet, response to thrombin PAR4 contributes to the predominant procoagulant microparticle formation, increased fibrin deposition, and initiation of platelet-stimulated inflammation. In addition, PAR4 is expressed in other cell types, including endothelial cells. Under inflammatory conditions, PAR4 is overexpressed via epigenetic demethylation of the PAR4 gene,

Indexed as

Acute Kidney InjuryRenal Insufficiency, ChronicAnimalsEndothelial CellsFibrosisInflammationIschemiaKidneyMiceMice, KnockoutReceptors, ThrombinReperfusion InjuryThrombinprotease-activated receptor 4Receptors, ThrombinThrombinacute kidney injuryF2RL3kidney fibrosisPAR4UUO

Identifiers

PMID38031732
PMCPMC11198992
OpenAlexW4389180095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.